Amedisys (NASDAQ:AMED) Stock, Quote.Headers.trade-ideas

Amedisys

Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Earnings

News

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

AMED

USPH

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Amedisys (NASDAQ: AMED) or U.S. Physical Therapy (NYSE: USPH).

AMED vs. USPH: Which Stock Is the Better Value Option?

Price Target

Pre-Market Outlook

ARCB

NFLX

PTGX

REGN


	Morgan Stanley cut the price target for  ArcBest Corporation  (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at $95.42 on Wednesday.


Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday

Analyst Color

Biotech

OPCH

Optum&#39;s Decision To Target Amedisys Is Intriguing, Says Analyst

Amedisys Inc

AMEDEO AIR FOUR PLUS LTD by AMEDEO AIR FOUR PLUS LTD

Contessa Health, A Subsidiary Of Amedisys Announced They Have Been Selected By The Centers For Medicare & Medicaid Services To Participate In A New Medicare Alternative Payment Model Designed To Support People Living With Dementia And Their Caregivers

Deutsche Bank analyst Justin Bowers downgrades Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) from Buy to Hold and maintains the price target from $101 to $101.

Downgrades

Deutsche Bank Downgrades Amedisys to Hold, Maintains Price Target to $101

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Amedisys (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amed#NASDAQ">AMED</a>) or U.S. Physical Therapy (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usph#NYSE">USPH</a>). But which of these two stocks is more attractive to value investors? We&#39;ll need to take a closer look to find out.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Amedisys has a Zacks Rank of #2 (Buy), while U.S. Physical Therapy has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that AMED likely has seen a stronger improvement to its earnings outlook than USPH has recently. But this is just one factor that value investors are interested in.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
AMED currently has a forward P/E ratio of 21.14, while USPH has a forward P/E of 34.11. We also note that AMED has a PEG ratio of 2.37. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company&#39;s expected earnings growth rate. USPH currently has a PEG ratio of 3.77.
Another notable valuation metric for AMED is its P/B ratio of 2.80. The P/B ratio is used to compare a stock&#39;s market value with its book value, which is defined as total assets minus total liabilities. For comparison, USPH has a P/B of 3.04.
These are just a few of the metrics contributing to AMED&#39;s Value grade of B and USPH&#39;s Value grade of C.
AMED is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that AMED is likely the superior value option right now.
<a href="https://www.zacks.com/stock/news/2310183/amed-vs-usph-which-stock-is-the-better-value-option?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2310183">To read this article on Zacks.com click here.</a>

Cantor Fitzgerald analyst Sarah James reiterates Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Neutral and maintains $101 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target

Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.18 by 11.86 percent. This is a 3.65 percent decrease over earnings of $1.37 per share from the same period last year. The company reported quarterly sales of $591.19 million which beat the analyst consensus estimate of $578.82 million by 2.14 percent. This is a 6.91 percent increase over sales of $552.97 million the same period last year.

Earnings Beats

Amedisys Q2 EPS $1.32 Beats $1.18 Estimate, Sales $591.19M Beat $578.82M Estimate

William Blair analyst Matt Larew downgrades Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) from Outperform to Market Perform.

William Blair Downgrades Amedisys to Market Perform

Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $1.02 by 0.98 percent. The company reported quarterly sales of $571.400 million which beat the analyst consensus estimate of $565.380 million by 1.06 percent. This is a 2.70 percent increase over sales of $556.389 million the same period last year.

Amedisys Q1 2024 Adj EPS $1.03 Beats $1.02 Estimate, Sales $571.400M Beat $565.380M Estimate

Raymond James analyst John Ransom maintains Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) from Market Perform to Market Perform.

Raymond James Maintains Market Perform on Amedisysto Market Perform

RBC Capital analyst Ben Hendrix maintains Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Outperform and raises the price target from $97 to $100.

RBC Capital Maintains Outperform on Amedisys, Raises Price Target to $100

Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $0.940 per share which missed the analyst consensus estimate of $1.030 by 8.74 percent. The company reported quarterly sales of $570.800 million which beat the analyst consensus estimate of $567.713 million by 0.54 percent. This is a 1.55 percent increase over sales of $562.064 million the same period last year.

Earnings Misses

Amedisys Q4 2023 Adj EPS $0.940 Misses $1.030 Estimate, Sales $570.800M Beat $567.713M Estimate

Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $1.03 by 8.74 percent. The company reported quarterly sales of $570.80 million which beat the analyst consensus estimate of $567.71 million by 0.54 percent. This is a 1.55 percent increase over sales of $562.06 million the same period last year.

Amedisys Q4 2023 Adj EPS $0.94 Misses $1.03 Estimate, Sales $570.80M Beat $567.71M Estimate

Amedisys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of infection testing, ultimately facilitating better patient care and outcomes. &nbsp;
Advanced molecular testing revolutionizes the diagnosis and management of infections, as it delivers rapid and precise results, ultimately enabling quicker initiation of appropriate treatment interventions. With improved accuracy, sensitivity and specificity, molecular testing significantly enhances the ability to identify infectious pathogens, supporting timely and targeted care strategies.
"We are excited to integrate molecular testing capabilities into our infection diagnosis protocols," states Cyndi Shook, Senior Vice President of Clinical Operations at Amedisys. "This advancement represents a significant step in our ongoing commitment to providing the highest quality of care to our patients. By leveraging the latest in diagnostic technology, we can further enhance the accuracy and speed of infection testing, allowing us to tailor treatment plans to the individual needs of each patient."
"Patients Choice Laboratories is excited to partner with Amedisys, one of the leaders in the home health industry, in an effort to improve outcomes for patients suffering from infectious diseases," said Brad Moss, President at Patients Choice Laboratories. "Our automated pre-analytical, analytical and post-analytical processes in molecular technologies provide the necessary clinical decision support so that treatments are targeted and successful."
"According to the CDC, more than one-third of deaths of people over the age of 65 are caused by infectious diseases, thus making turnaround time critical so that the most appropriate treatment(s) are deployed in the early stages of infection," added Thomas Payne, Chief Operations Officer at Patients Choice Laboratories. "Molecular testing provides the speed and accuracy needed to detect pathogens across our entire infectious disease platform."
"Our partnership with Patient Choice Laboratories aligns seamlessly with our dedication to delivering exceptional care and optimizing patient outcomes," added Barbara Andazola, Vice President of Clinical Practice, Strategy and Programs at Amedisys. "By incorporating molecular testing into our infection diagnosis protocols, we are empowering our care teams to provide more accurate and effective treatments, ultimately reducing the impact of infections and preventing related hospitalizations."
Amedisys has implemented comprehensive protocols and training to ensure seamless integration of molecular testing into its care centers. The rollout of this innovative approach to infection diagnosis underscores the organization's commitment to staying at the forefront of healthcare advancements and technology, ultimately providing its patients with the highest standard of care and support.
For more information about Amedisys Home Health and its advanced molecular testing capabilities, please visit <a href="http://www.amedisys.com/">www.amedisys.com</a>.

Amedisys Offers Molecular Testing For Rapid And Accurate Infection Diagnosis In Collaboration With Patient Choice Laboratories

Richard Ashworth, President and CEO at Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), reported a large exercise of company stock options on December 28, according to a new SEC filing.
What Happened: Ashworth, President and CEO at Amedisys, made a strategic move by exercising stock options for 11,237 shares of AMED as detailed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000896262/000089626223000081//Archives/edgar/data/896262/000089626223000081/0000896262-23-000081-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $171,027.
Amedisys shares are trading down 0.0% at $95.04 at the time of this writing on Friday morning. Since the current price is $95.04, this makes Ashworth's 11,237 shares worth $171,027.
<h3>Get to Know Amedisys Better</h3>
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
<h3>Amedisys's Financial Performance</h3>
Revenue Growth: Amedisys's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2023, the company experienced a revenue decline of approximately -0.31%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 43.98%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Amedisys's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.8.
</li>
</ul>
Debt Management: Amedisys's debt-to-equity ratio is below the industry average. With a ratio of 0.47, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 1188.0 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.39, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Amedisys's EV/EBITDA ratio of 25.02 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000896262">Check Out The Full List Of Amedisys's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Richard Ashworth Exercises Options, Realizes $171K

Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) reported quarterly earnings of $0.98 per share which missed the analyst consensus estimate of $1.08 by 9.26 percent. This is a 14.78 percent decrease over earnings of $1.15 per share from the same period last year. The company reported quarterly sales of $556.20 million which missed the analyst consensus estimate of $561.27 million by 0.90 percent. This is a 0.32 percent decrease over sales of $557.99 million the same period last year.

Amedisys Q3 Adj. EPS $0.98 Misses $1.08 Estimate, Sales $556.20M Miss $561.27M Estimate

Cantor Fitzgerald has decided to maintain its Neutral rating of Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) and raise its price target from $100.00 to $101.00.
Shares of Amedisys are trading up 0.11% over the last 24 hours, at $93.61 per share.
A move to $101.00 would account for a 7.89% increase from the current share price.
<h3>About Amedisys</h3>
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cantor Fitzgerald Maintains Neutral Rating for Amedisys: Here's What You Need To Know

Cantor Fitzgerald analyst Sarah James maintains Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Neutral and raises the price target from $100 to $101.

Cantor Fitzgerald Maintains Neutral on Amedisys, Raises Price Target to $101

TD Cowen analyst Gary Taylor maintains Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Market Perform and raises the price target from $84 to $101.

TD Cowen Maintains Market Perform on Amedisys, Raises Price Target to $101

Over the past 3 months, 11 analysts have published their opinion on Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
According to 11 analyst offering 12-month price targets in the last 3 months, Amedisys has an average price target of $98.82 with a high of $115.00 and a low of $84.00. 
Below is a summary of how these 11 analysts rated Amedisys over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1690466417_0.png" alt="price target chart" />
This current average has decreased by 1.74% from the previous average price target of $100.57. 
<a href="https://www.benzinga.com/quote/AMED/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amedisys analyst ratings.</a>
<h1>How Are Analyst Ratings Determined?</h1>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 11 Analyst Ratings Have To Say About Amedisys

Credit Suisse analyst Jonathan Yong reiterates Amedisys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) with a Neutral and maintains $101 price target.

Credit Suisse Reiterates Neutral on Amedisys, Maintains $101 Price Target

Amedisys&nbsp; Non-GAAP EPS of $1.32 beats by $0.14, revenue of $591.2M beats by $9.38M

An announcement from Amedisys (AMED) is now available. The company has released its second quarter supplemental slides, providing investors a curre...

Amedisys Releases Q2 Supplemental Financial Slides

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Amedisys (NASDAQ:<a href="https://investorplace.com/stock-quotes/amed-stock-quote/">AMED</a>) just reported results for the second quarter of 2024.<ul><li>Amedisys reported earnings per share of $1.32. This was above the analyst estimate for EPS of $1.18.</li><li>The company reported revenue of $591.19 million.</li><li>This was 2.14% better than the analyst estimate for revenue of $578.82 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/07/amed-stock-earnings-amedisys-for-q2-of-2024/">AMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q2 2024

In a report released today, David S Macdonald from Truist Financial assigned a Hold rating to Amedisys (AMED – Research Report). The company's shar...

Truist Financial Gives a Hold Rating to Amedisys (AMED)

TD Cowen analyst Gary Taylor maintained a Hold rating on Amedisys (AMED – Research Report) today and set a price target of $101.00. The company's s...

Amedisys (AMED) Gets a Hold from TD Cowen

Ryan Langston, an analyst from TD Cowen, maintained the Hold rating on Amedisys (AMED – Research Report). The associated price target is $101.00. R...

Amedisys: Hold Rating Affirmed Amidst Modest EBITDA Adjustments and Acquisition Offer

Top Merger Stocks Held By Fund Managers, Mid-Q3 2024

Amedisys (AMED) has provided an announcement. Amedisys, Inc. is seeing the departure of its Chief Information Officer, Michael P. North, at the end...

Amedisys CIO Michael North Exits with $3M Severance Package

BrightSpring Health Services: Evaluating The Investment Case Seven Months Post-IPO

Amedisys sale to UnitedHealth unlikely to be done until at least end of November

ADUS

ANSS

AXNX

BTSG

CPRI

CTLT

JNPR

LSXMA

LSXMB

LSXMK

SRDX

Press Releases

Amedisys Celebrates National Quality Week

Amedisys Reports Third Quarter 2023 Financial Results

Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis

Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results

Amedisys Reports First Quarter 2024 Financial Results

AREX Capital Management Issues Letter to Enhabit Stockholders Regarding the Need for Dramatic Changes to Board Composition

Amedisys Reports Second Quarter 2024 Financial Results

Contracts

Contessa Selected by Centers for Medicare & Medicaid Services to Test Medicare Dementia Care Model

EHAB

TUES

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Amedisys

Amedisys (AMED) Forecast

Amedisys (NASDAQ:AMED) Stock, Quote.Headers.trade-ideas